Every pet weight-loss drug in development, in one table.
No GLP-1 drug is FDA-approved for cats or dogs. 4 programmes are tracked here, 2 of them GLP-1s. The furthest along is a pivotal study in cats that reads out in 2027. Everything below states its sponsor, its phase, when it is expected to report and whether that date came from the company or from reporting.
| Programme | Species | Expected readout | Status | Detail |
|---|---|---|---|---|
| Pivotal studyThe study intended to support approval | ||||
| OKV-119Okava PharmaceuticalsMEOW-1 study | Cats | Summer 2027Estimated, not company-confirmed | Dosing. The MEOW-1 study is running in client-owned overweight and obese cats under an FDA-CVM Investigational New Animal Drug application, with weight and health metrics measured at three and six months. CNBC reported on 18 July 2026 that top-line results of both feline GLP-1 trials are expected later this year. That sentence is unattributed, covers the two programmes in one clause, and gives no Okava-specific date; Okava itself has stated no readout date. It is recorded here because readers arrive carrying it, and it is not adopted as the MEOW-1 window: the estimate below follows the trial's own clock, a December 2025 start, an implant releasing for up to six months, a three-month primary period with an optional three-month extension, and cats still being dosed in mid-2026. | Full statusFull status for OKV-119 |
| Pilot studyEarly study, small numbers | ||||
| AKS-562cAkston Biosciences | Cats | H2 2026Estimated, not company-confirmed | The Cornell study in client-owned overweight cats, 70 enrolled with an option to extend, has published nothing. Cornell's own award record puts the project period at July 2025 to June 2026 and describes an 11-week treatment period, principal investigator Patrick Carney. The funded period has therefore closed without a published result. The safety data Akston presented at the 2026 ACVIM Forum came from a separate preclinical study in 16 healthy research cats: well tolerated over 12 weeks, no treatment-related toxicity, no antidrug antibodies. Those are two different cohorts and only the second has read out. | Full statusFull status for AKS-562c |
| Not GLP-1sTracked as regulatory and historical context | ||||
| LOY-002LoyalNot a GLP-1 | Dogs | Company-projected launch before end of 2026Estimated, not company-confirmed | Two of three FDA technical sections accepted: reasonable expectation of effectiveness in February 2025 and target animal safety in January 2026. The manufacturing section remains outstanding. | Full statusFull status for LOY-002 |
| Slentrol (dirlotapide)Pfizer Animal HealthNot a GLP-1 | Dogs | Not applicable | The first and so far only FDA-approved canine weight-loss drug. Approved 2007, voluntarily discontinued in 2013. | Full statusFull status for Slentrol (dirlotapide) |
Nothing in this table is FDA-approved for weight loss in cats or dogs. A programme being in a pivotal study is not an approval, and an expected readout is not a result. Dates marked “estimated” come from reporting or analysis, not from the sponsor. Last verified 2026-08-02.
Get notified when pet GLP-1 medications arrive.
One email when there's real news: Okava MEOW-1 results, FDA filings, the first cat & dog GLP-1 launches. Nothing else.
We never share your email. Unsubscribe in one click. Powered by Resend.
Why a recommendation, a trial and an approval are three different things
A drug in a pivotal study has not been approved. A company projecting a launch date has not been cleared to launch. And a drug that was once approved can be withdrawn, which is exactly what happened to Slentrol, the only canine weight-loss drug the FDA has ever cleared. It is in this table for that reason: it is the proof the category can clear FDA, and the proof that clearing FDA is not the end of the story.
Nothing here is veterinary advice. Do not give your pet a human GLP-1 medication without veterinary guidance.